CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
Abstract Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast cancer. One randomized clinical tria...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-07-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-017-0029-3 |